कंपनी का अवलोकन
Journey Medical Corporation operates as a commercial-stage pharmaceutical entity dedicated to the development and commercialization of therapeutic products for dermatological conditions within the United States market. The company functions within the broader healthcare sector, specifically categorized under the industry of drug manufacturers specializing in both specialty and generic pharmaceuticals. This operational scale is characterized by a market capitalization of $172.60M, an annual revenue generation of $61.86M, and a workforce comprising 58 employees. These valuation and revenue figures indicate that the company holds a mid-cap position in the pharmaceutical landscape, suggesting it possesses the resources for commercialization while maintaining a lean organizational structure typical of specialized drug developers.
वित्तीय स्वास्थ्य
The company reported a total revenue of $61.86M over the trailing twelve months, yet it recorded a net income loss of $-11,431,000, highlighting a significant disparity where costs and expenses substantially exceeded total revenue. This gap between revenue and net income reveals a challenging cost structure where operational expenditures and likely research or commercialization costs are draining profitability before reaching the bottom line. Additionally, the entity reported an EBITDA of $-3,914,000, indicating that even before financing costs and taxes, core operations are currently generating negative cash earnings. Free cash flow stands at $-8,353,750, which signifies that the company is consuming cash reserves to fund its operations and growth initiatives rather than generating surplus liquidity for distribution. In terms of profitability margins, the gross margin is 66.2%, reflecting the high value of the pharmaceutical products relative to the cost of goods sold, whereas the operating margin is -2.8% and the profit margin is -18.5%, indicating that operating expenses are eroding gross profits significantly. Regarding the balance sheet, total cash holdings of $24.09M are insufficient to cover total debt obligations of $25.40M, resulting in a debt-to-equity ratio of 79.73, which characterizes the balance sheet as leveraged rather than conservative. The current ratio of 1.79 suggests that the company holds sufficient current assets to cover its short-term liabilities, indicating a reasonable level of short-term liquidity despite the leverage. Return on Equity is recorded at -44.0% and Return on Assets is -5.8%, metrics that reveal that management has not yet achieved positive returns on the capital invested in the company's equity or asset base.
मूल्यांकन आकलन
Valuation metrics for Journey Medical Corporation present a complex picture due to the lack of traditional earnings multiples, as the P/E Ratio (TTM) is listed as N/A and the forward P/E is negative at -86.50. The negative forward P/E implies that the market is pricing in future earnings that are expected to be negative or that the company is currently unprofitable, making traditional earnings-based valuation methods inapplicable. Instead, the price-to-book ratio of 4.42 indicates that the market is valuing the company at a significant premium over its book value, potentially reflecting high growth expectations or intangible asset value not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.79 and the EV/EBITDA of -36.57 further suggest that investors are focusing on revenue multiples and enterprise value relative to earnings before interest, taxes, depreciation, and amortization, which are currently negative. The stock price fluctuates between a 52-week high of $9.55 and a 52-week low of $4.31, and without a specific current share price provided in the facts, the trading position relative to this range cannot be calculated, but the wide spread indicates high price volatility. The beta value of 1.04 suggests that the stock's price volatility moves in line with the broader market, exhibiting slightly higher sensitivity to market fluctuations than a beta of 1.0 would indicate.
Growth & Income
Revenue growth for the trailing twelve months stands at 18.1%, demonstrating a robust expansion in sales, whereas earnings growth is listed as N/A due to the company's current unprofitable status. Because earnings growth is not applicable in the traditional sense due to net losses, the revenue expansion is the primary driver of growth, implying that the company is prioritizing top-line expansion over immediate profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings, if any, or capital are reinvested directly into business operations rather than distributed to shareholders. Consequently, the overall growth and income profile is defined by aggressive revenue expansion funded by cash reserves and debt, with no reliance on dividend income for investors seeking current yield.